Previous studies have demonstrated that CyR61 upregulation can activate the Wnt/β-catenin pathway in gliomas [52] and that β-catenin activation or overexpression can upregulate CyR61 in hepatocellular carcinomas and pancreatic cancers [53,54]. This evidence concerns the gene CCN1 and pancreatic neoplasm.